Recombinant Osteonectin/SPARC Monoclonal Antibody

SKU: AN300525P

Size::

Storage:This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Shipping:Ice bag

Exp date:12 months

Category ID_II:Primary Antibodies

Category ID_III:Recombinant Antibodies;Monoclonal Antibodies

Abbreviation:SPARC

Target Synonym:RP23-465I;AA517111;BM-40;ON;RP23-465I4.1;Secreted Protein Acidic and Rich in Cysteine;Sparc

Research Areas:

Conjugation:Unconjugated

Host:Rabbit

Species reactivity:Mouse

Application:WB;IP

Isotype:IgG

Clonality:Monoclonal

Clone NO.:8A5

UNIProt ID:P07214

Accession:

Background:Secreted protein acidic and rich in cysteine (SPARC), also known as Osteonectin (ON), is a member of the SPARC family. SPARC consists of three domains: an EF-hand domain, a follistatin-like domain and a Kazal-like domain, and each of which has independent activity and unique properties. The activity of SPARC is context- and cell-type-dependent, which is highlighted by the fact that SPARC has shown seemingly contradictory effects on tumor progression in both clinical correlative studies and in animal models. The location of SPARC in the nuclear matrix of certain proliferating cells, but only in the cytosol of postmitotic neurons, indicates potential functions of SPARC as a nuclear protein, which might be involved in the regulation of cell cycle progression and mitosis. It functions not only to modulate cell-cell and cell-matrix interactions, but its de-adhesive and growth inhibitory properties in non-transformed cells have led to studies to assess its role in cancer. Its divergent actions reflect the complexity of this protein, because in certain types of cancers, such as melanomas and gliomas, SPARC is associated with a highly aggressive tumor phenotype, while in others, mainly ovarian, neuroblastomas and colorectal cancers, SPARC may function as a tumor suppressor. Recent studies have also demonstrated a role for SPARC in sensitizing therapy-resistant cancers. Notably, SPARC is linked to human obesity.

Concentration:1 mg/mL

Immunogen:Recombinant Mouse Osteonectin/SPARC protein

Buffer:0.2 μm filtered solution in PBS

Purification method:Protein A

Dilution:WB 1:500-1:1000;IP 0.2-1 μL/mg of lysate

Calculated MW:35 kDa

ObservedMW:40 kDa